Evidence Summaries The addition of licensed doses of anti-leukotrienes to add-on therapy to inhaled glucocorticoids appears to bring modest improvement in lung function.
A Cochrane review 1 included 16 trials in the meta-analysis. In symptomatic patients, addition of licensed doses of anti-leukotrienes to ICS resulted in a non-significant reduction in the risk of exacerbations requiring systemic steroids: Relative Risk (RR) 0.64; 95% Confidence Interval (CI) 0.38 to 1.07). A modest improvement group difference in PEF was seen (Weighted Mean Difference (WMD) 7.7 l/min; 95% CI 3.6 to 11.8 l/min) together with decrease in use of rescue short-acting beta2-agonist use (WMD 1 puff/week; 95% CI 0.5 to 2). With only 3 trials comparing the use of licensed doses of anti-leukotrienes with increasing the dose of inhaled glucocorticoids, no firm conclusion can be drawn about the equivalence of both treatment options. In ICS-sparing studies of patients who were well controlled at baseline, addition of anti-leukotrienes produced no overall difference in dose of inhaled glucocorticoids (WMD –21 µg/d, 95%CI –65, 23 µg/d), but it was associated with fewer withdrawals due to poor asthma control (RR 0.63, 95% CI 0.42 to 0.95).
Authors' conclusion: Although addition of anti-leukotrienes to inhaled glucocorticoids appears comparable to increasing the dose of inhaled steroids, the power of the review is insufficient to confirm the equivalence of both treatment options. Addition of anti-leukotrienes is associated with superior asthma control after glucocorticoid tapering; although the glucocorticoid-sparing effect cannot be quantified at present, it appears modest.
Comment: The quality of evidence is downgraded by sparse data.
. Ducharme F, Schwartz Z, Hicks G, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004;(2):CD003133. [PMID:15106191]
Copyright © 2023 Duodecim Medical Publications Limited.
"Addition of Anti-leukotriene Agents to Inhaled Corticosteroids for Chronic Asthma." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455503/all/Addition_of_anti_leukotriene_agents_to_inhaled_corticosteroids_for_chronic_asthma.
Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455503/all/Addition_of_anti_leukotriene_agents_to_inhaled_corticosteroids_for_chronic_asthma. Accessed June 10, 2023.
Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/455503/all/Addition_of_anti_leukotriene_agents_to_inhaled_corticosteroids_for_chronic_asthma
Addition of Anti-leukotriene Agents to Inhaled Corticosteroids for Chronic Asthma [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 June 10]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455503/all/Addition_of_anti_leukotriene_agents_to_inhaled_corticosteroids_for_chronic_asthma.
TY - ELEC
T1 - Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma
ID - 455503
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455503/all/Addition_of_anti_leukotriene_agents_to_inhaled_corticosteroids_for_chronic_asthma
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine